|

A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting

RECRUITINGSponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Actively Recruiting
SponsorJuno Therapeutics, Inc., a Bristol-Myers Squibb Company
Started2025-02-04
Est. completion2044-09-30
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT06788652

Summary

The purpose of this study is to understand the long-term safety and effectiveness of lisocabtagene maraleucel (liso-cel) for the treatment of Mantle Cell Lymphoma (MCL).

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

• Participants must have been treated in the postmarketing setting with at least 1 infusion of lisocabtagene maraleucel (Liso-cel) used for the treatment of Mantle Cell Lymphoma (MCL) according to the FDA-approved indication and dose range (ie, per the US Prescribing Information) and with a product meeting the specifications for commercial release approved in the USA

Exclusion Criteria:

* Participants known to be participating in investigational studies at the time of liso-cel infusion.
* Participants treated with non-conforming CAR T-cell product.

Conditions2

CancerMantle Cell Lymphoma (MCL)

Locations1 site

Center for International Blood and Marrow Transplant Research (CIBMTR)
Milwaukee, Wisconsin, 53226

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.